4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2025)
Historic Current Leases for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $5.7 million.
- 4D Molecular Therapeutics' Current Leases rose 1186.41% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 1186.41%. This contributed to the annual value of $5.6 million for FY2024, which is 7900.92% up from last year.
- Per 4D Molecular Therapeutics' latest filing, its Current Leases stood at $5.7 million for Q3 2025, which was up 1186.41% from $5.7 million recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Current Leases high stood at $5.7 million for Q2 2025, and its period low was $1.2 million during Q4 2021.
- Its 5-year average for Current Leases is $3.6 million, with a median of $3.1 million in 2023.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Current Leases skyrocketed by 11567.83% in 2022, and later surged by 299.71% in 2024.
- 4D Molecular Therapeutics' Current Leases (Quarter) stood at $1.2 million in 2021, then surged by 115.68% to $2.7 million in 2022, then increased by 18.61% to $3.1 million in 2023, then skyrocketed by 79.01% to $5.6 million in 2024, then increased by 1.03% to $5.7 million in 2025.
- Its Current Leases stands at $5.7 million for Q3 2025, versus $5.7 million for Q2 2025 and $5.7 million for Q1 2025.